Digest Network Come funziona
Network
/
Società
Ak
Non verificato

Akamis Bio

Di cosa scriviamo

BiotecnologiaIndustriaMedicina - VarieOncologiaSalute

6 comunicati stampa

Guarda tutti i comunicati
14/10/2025
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Sanità
Biotecnologia
Industria
Akamis Bio Receives FDA Fast Track Designation for NG-350A for the Treatment of Mismatch Repair-Proficient Locally Advanced Rectal Cancer
Fonte
Akamis Bio
Emittente
Business Wire
1.00
0
12/08/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Mercato del lavoro
Akamis Bio Announces the Appointment of Andrew Hirsch to the Company’s Board of Directors
Fonte
Akamis Bio
Emittente
Business Wire
1.00
0
06/05/2025
Mercato del lavoro
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Akamis Bio Broadens Leadership Team with Key Executive Appointments
Fonte
Akamis Bio
Emittente
Business Wire
1.00
0
03/04/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Akamis Bio Announces Enrollment of First Patient in Phase 1b FORTRESS Trial of NG-350A in Patients with Locally Advanced Rectal Cancer
Fonte
Akamis Bio
Emittente
Business Wire
1.00
0
17/12/2024
Mercato del lavoro
Industria
Medicina - Varie
Associazioni/Professionisti
Biotecnologia
Sanità
Salute
Oncologia
Akamis Bio Announces $60 Million in Funding Linked to Series A Prime Financing and New Strategic Partnership
Fonte
Akamis Bio
Emittente
Business Wire
1.00
0
23/10/2024
Industria
Oncologia
Salute
Scienza
Sanità
Biotecnologia
Akamis Bio Announces Publication Detailing Initial Proof of Mechanism for NG-350A, an IV-Dosed Tumor Gene Therapy Delivering a CD40 Agonist Payload
Fonte
Akamis Bio
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0